090-71-3417

Caris - MI Tumor seek & PD-L1, tissue (FFPE) **

Tissue/ Formalin-fixed paraffin-embedded (FFPE) block

Received specimen to report 30 days (Slide received to report)

MI Tumor Seek (test by NGS), plus PD-L1 testing.

PD-1 (test by IHC) is an immunosuppressive protein molecule that is upregulated on activated T-cells and other immune cells. It is activated by binding to its ligand, PD-L1, an action that results in intracellular responses that reduce T-cell activation. Reports of aberrant PD-L1 expression in cancer cells have spurred the development of PD-1 and PD-L1 inhibitors. The U.S. Food and Drug Administration (FDA) recently approved an anti-PD-1 therapy, pembrolizumab (Keytruda), for the treatment of advanced or unresectable melanoma. Another anti-PD-1 agent, nivolumab, was recently approved in Japan for the treatment of unresectable melanoma.

Next-generation sequencing (NGS)

All Biomarker Analysis includes:
DNA Mutation, Copy Number Alterations, Insertions/Deletions    
Genomic Signatures: MSI, TMB
RNA Fusion Analysis
IHC: PD-L1

Comprehensive Genomic Profiling, Tissue